Cross clinical-experimental-computational qualification of in silico drug trials on human cardiac purkinje cells for proarrhythmia risk prediction. Trovato C, Mohr M, Schmidt F, Passini E, Rodriguez B. Toxicology Letters. 2022. 4:992650. Partner involved: UOXF